Read by QxMD icon Read

Prostate Cancer and Prostatic Diseases

Amy J Weisman, Stephanie A Harmon, Timothy G Perk, Jens Eickhoff, Peter L Choyke, Karen A Kurdziel, William L Dahut, John L Humm, Andrea B Apolo, Steven M Larson, Michael J Morris, Scott B Perlman, Glenn Liu, Robert Jeraj
BACKGROUND: Bone flare has been observed on 99m Tc-MDP bone scans of patients with metastatic castration-resistant prostate cancer (mCRPC). This exploratory study investigates bone flare in mCRPC patients receiving androgen receptor (AR) inhibitors using 18 F-NaF PET/CT. METHODS: Twenty-nine mCRPC patients undergoing AR-inhibiting therapy (abiraterone, orteronel, enzalutamide) received NaF PET/CT scans at baseline, week 6, and week 12 of treatment. SUV metrics were extracted globally for each patient (SUV) and for each individual lesion (iSUV)...
November 9, 2018: Prostate Cancer and Prostatic Diseases
Rachael L Sherrer, Zachary A Glaser, Jennifer B Gordetsky, Jeffrey W Nix, Kristin K Porter, Soroush Rais-Bahrami
BACKGROUND: Multiparametric magnetic resonance imaging (MP-MRI) and MRI/ultrasound (US) fusion-guided biopsy are becoming more widely used techniques for prostate cancer (PCa) diagnosis and management. However, their widespread adoption and use, where available, are limited by cost and added time. These limitations could be minimized if a biparametric MRI (BP-MRI) focusing on T2-weighted and diffusion-weighted imaging is performed. Herein we report the cancer detection rate of BP-MRI compared with full MP-MRI...
November 9, 2018: Prostate Cancer and Prostatic Diseases
Enrique González-Billalabeitia, Vincenza Conteduca, Daniel Wetterskog, Anuradha Jayaram, Gerhardt Attard
The genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) differs from that of the primary tumor and is dynamic during tumor progression. The real-time and repeated characterization of this process via conventional solid tumor biopsies is challenging. Alternatively, circulating cell-free DNA (cfDNA) containing circulating tumor DNA (ctDNA) can be obtained from patient plasma using minimally disruptive blood draws and is amenable to sequential analysis. ctDNA has high overlap with the genomic sequences of biopsies from metastases and has the advantage of being representative of multiple metastases...
November 9, 2018: Prostate Cancer and Prostatic Diseases
Jonne Åkerla, Jori S Pesonen, Antti Pöyhönen, Jukka Häkkinen, Juha Koskimäki, Heini Huhtala, Teuvo L J Tammela, Anssi Auvinen
BACKGROUND: The usefulness of lower urinary tract symptoms (LUTS) as mortality risk factors remains unclear. Repeated assessments are required to take into account symptom fluctuation and de novo symptom appearance. The study objective was to evaluate mortality in relation to three urinary storage symptoms-urgency, daytime frequency, and nocturia-in middle-aged and elderly men, considering also other time-varying factors during follow-up. METHODS: A mail survey of a population-based cohort of men initially aged 50, 60, and 70 years was conducted in Finland in 1994, 1999, 2004, and 2009...
November 8, 2018: Prostate Cancer and Prostatic Diseases
Michael A Liss, Osamah Al-Bayati, Jonathan Gelfond, Martin Goros, Sarah Ullevig, John DiGiovanni, Jill Hamilton-Reeves, Denise O'Keefe, Dean Bacich, Brandi Weaver, Robin Leach, Ian M Thompson
BACKGROUND: To study the association of nutrient intake measured by baseline food frequency questionnaire and risk of subsequent prostate cancer (PCa) in the SABOR (San Antonio Biomarkers of Risk) cohort study. METHODS: After IRB approval, more than 1903 men enrolled in a prospective cohort from 2000 to 2010 as part of the SABOR clinical validation site for the National Cancer Institute Early Detection Research Network. Food and nutrient intakes were calculated using a Food Frequency Questionnaire...
November 1, 2018: Prostate Cancer and Prostatic Diseases
Christopher B Riedinger, Richard J Fantus, Richard S Matulewicz, Ryan P Werntz, Joseph F Rodriguez, Norm D Smith
BACKGROUND: Transurethral resection of the prostate is the most commonly performed procedure for the management of benign prostatic obstruction. However, little is known about the effect surgical duration has on complications. We assess the relationship between operative time and TURP complications using a modern national surgical registry. METHODS: We queried the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) from 2006 to 2016 for patients undergoing TURP...
November 1, 2018: Prostate Cancer and Prostatic Diseases
James L Mohler, Susan Halabi, Stephen T Ryan, Ali Al-Daghmin, Mitchell H Sokoloff, Gary D Steinberg, Ben L Sanford, James A Eastham, Philip J Walther, Michael J Morris, Eric J Small
BACKGROUND: To evaluate efficacy and morbidity prospectively in a contemporary multi-institutional salvage radical prostatectomy (SRP) series. METHODS: Forty-one men were enrolled between 1997 and 2006, who suffered biopsy-proven recurrent prostate cancer (CaP) after receiving ≥ 60c Gy radiation as primary treatment for cT1-2 NX M0 disease. Surgical morbidity, quality of life, biochemical progression-free survival (BPFS) and overall survival (OS) were evaluated...
November 1, 2018: Prostate Cancer and Prostatic Diseases
Anders E Berglund, Robert J Rounbehler, Travis Gerke, Shivanshu Awasthi, Chia-Ho Cheng, Mandeep Takhar, Elai Davicioni, Mohammed Alshalalfa, Nicholas Erho, Eric A Klein, Stephen J Freedland, Ashley E Ross, Edward M Schaeffer, Bruce J Trock, Robert B Den, John L Cleveland, Jong Y Park, Jasreman Dhillon, Kosj Yamoah
BACKGROUND: Prostate cancer (PCa) tumors harboring translocations of ETS family genes with the androgen responsive TMPRSS2 gene (ETS+ tumors) provide a robust biomarker for detecting PCa in approximately 70% of patients. ETS+ PCa express high levels of the androgen receptor (AR), yet PCa tumors lacking ETS fusions (ETS-) also express AR and demonstrate androgen-regulated growth. In this study, we evaluate the differences in the AR-regulated transcriptomes between ETS+ and ETS- PCa tumors...
October 26, 2018: Prostate Cancer and Prostatic Diseases
Renata Zelic, Valentina Fiano, Ericka M Ebot, Sarah Coseo Markt, Chiara Grasso, Morena Trevisan, Laura De Marco, Luisa Delsedime, Daniela Zugna, Lorelei A Mucci, Lorenzo Richiardi
BACKGROUND: Germline variants in DNA methyltransferase 3B (DNMT3B) may influence DNMT3B enzymatic activity, which, in turn, may affect cancer aggressiveness by altering DNA methylation. METHODS: The study involves two Italian cohorts (NTAT cohort, n = 157, and 1980s biopsy cohort, n = 182) and two U.S. cohorts (Health Professionals Follow-Up Study, n = 214, and Physicians' Health Study, n = 298) of prostate cancer (PCa) patients, and a case-control study of lethal (n = 113) vs indolent (n = 290) PCa with DNMT3B mRNA expression data nested in the U...
October 19, 2018: Prostate Cancer and Prostatic Diseases
Jui-Ming Liu, Tien-Hsing Chen, Heng-Chang Chuang, Chun-Te Wu, Ren-Jun Hsu
BACKGROUND: Androgen deprivation therapy (ADT) has been reported to increase the risk of dementia. Statin use decreases the risk of dementia. This study is aimed to investigate the association of statin use and dementia in type 2 diabetic (T2DM) patients receiving ADT. METHODS: Using the National Health Insurance Research Database of Taiwan, we conducted a population-based nationwide cohort study of T2DM patients newly diagnosed with prostate cancer (PCa) between 1998 and 2013...
October 18, 2018: Prostate Cancer and Prostatic Diseases
Katelyn A Barnes, Lauren E Ball, Daniel A Galvão, Robert U Newton, Suzanne K Chambers
BACKGROUND: To review the evidence available to support clinical practice guidelines for dietary interventions aimed at mitigating the side effects of androgen deprivation therapy (ADT) in men with prostate cancer, and to identify future research priorities. METHODS: An analytical model was designed to select and interpret evidence for the effect of dietary interventions on ADT side effects. Key terms identified articles that investigated dietary interventions to mitigate ADT side effects among men treated for prostate cancer...
October 2, 2018: Prostate Cancer and Prostatic Diseases
Lucy A M Simmons, Abi Kanthabalan, Manit Arya, Tim Briggs, Susan C Charman, Alex Freeman, James Gelister, Charles Jameson, Neil McCartan, Caroline M Moore, Jan van der Muelen, Mark Emberton, Hashim U Ahmed
BACKGROUND: Men with negative prostate biopsies or those diagnosed with low-risk or low-volume intermediate-risk prostate cancers often require a second prostate biopsy prior to a treatment decision. Prostate HistoScanning (PHS) is an ultrasound imaging test that might inform prostate biopsy in such men. METHODS: PICTURE was a prospective, paired-cohort validating trial to assess the diagnostic accuracy of imaging in men requiring a further biopsy (clinicaltrials...
October 2, 2018: Prostate Cancer and Prostatic Diseases
Colette A Whitney, Lauren E Howard, Stephen J Freedland, Amanda M DeHoedt, Christopher L Amling, William J Aronson, Matthew R Cooperberg, Christopher J Kane, Martha K Terris, Timothy J Daskivich
BACKGROUND: Understanding competing risks for mortality is critical in determining prognosis among men with non-metastatic castration-resistant prostate cancer (nmCRPC), a disease state that often affects older men and has substantial heterogeneity in risk of cancer mortality. We sought to determine the impact of age, comorbidity, and PSA doubling time (PSADT) on competing risks for mortality in men with nmCRPC. METHODS: We conducted a retrospective analysis of 1238 patients diagnosed with nmCRPC in 2000-2015 in the SEARCH database...
October 2, 2018: Prostate Cancer and Prostatic Diseases
Wei Phin Tan, Dimitri Papagiannopoulos, Kalyan C Latchamsetty, Nathaniel Wilson, Nicholas O'Block, Lester Raff, Alfredo Mena Lora, Christopher L Coogan, Michael R Abern
IMPORTANCE: Fluoroquinolone (FQ)-resistant rectal vault flora is associated with infectious complications in men undergoing transrectal ultrasound-guided prostate needle biopsy (TRUS-PNB). OBJECTIVE: To determine the patient factors that predict FQ-resistant rectal cultures in men who are undergoing transrectal ultrasound-guided prostate needle biopsy. METHODS: An IRB approved retrospective review of 6183 consecutive men who had undergone a rectal swab culture in preparation for TRUS-PNB between January 2013 and December 2014 was performed...
October 2, 2018: Prostate Cancer and Prostatic Diseases
Marie-Rose B S Crombag, Merel van Nuland, Andries M Bergman, Hilde Rosing, Jan H M Schellens, Alwin D R Huitema, Jos H Beijnen
BACKGROUND: Oral antiandrogen therapies are predominantly used in older men, but real-life studies evaluating the impact of age on pharmacokinetic exposure are lacking. This study aims to evaluate the impact of age on the pharmacokinetic profiles of abiraterone acetate and enzalutamide in clinical practice. PATIENTS AND METHODS: Retrospective observational study to evaluate the impact of age on the first steady-state sample of patients treated with abiraterone acetate or enzalutamide in routine daily clinical practice...
October 2, 2018: Prostate Cancer and Prostatic Diseases
Jeffrey J Tosoian, Liana B Guedes, Carlos L Morais, Mufaddal Mamawala, Ashley E Ross, Angelo M De Marzo, Bruce J Trock, Misop Han, H Ballentine Carter, Tamara L Lotan
BACKGROUND: Up to half of men with Gleason score 6 (GS6) prostate cancers initially managed with active surveillance (AS) will eventually require definitive therapy, usually due to tumor grade reclassification during follow-up. We examined the association between PTEN status on biopsy and subsequent clinicopathologic outcomes in men with GS6 cancers who enrolled in AS. METHODS: We performed a case-control study of men enrolled in the Johns Hopkins AS cohort with diagnostic biopsy tissue available for immunohistochemical (IHC) staining...
October 2, 2018: Prostate Cancer and Prostatic Diseases
Ryan W Dobbs, Neha R Malhotra, Michael R Abern, Daniel M Moreira
BACKGROUND: We sought to evaluate prostate cancer (PCa) characteristics and outcomes of Hispanics living in the United States by country of origin in the Surveillance, Epidemiology and End Results (SEER) program. METHODS: Retrospective analysis of 72,134 adult Hispanics with PCa between 1995 and 2014. Origin was Mexican (N = 16,995; 24%), South/Central American (N = 6949; 10%), Puerto Rican (N = 3582; 5%), Cuban (N = 2587; 4%), Dominican (N = 725; 1%), Hispanic not specified (NOS, N = 41,296; 57%), as coded by SEER...
October 2, 2018: Prostate Cancer and Prostatic Diseases
Andrew J Armstrong
No abstract text is available yet for this article.
October 2, 2018: Prostate Cancer and Prostatic Diseases
Donald L Bliwise, Lauren E Howard, Daniel M Moreira, Gerald L Andriole, Martin L Hopp, Stephen J Freedland
BACKGROUND: Nocturia (voids arising from sleep) is a ubiquitous phenomenon reflecting many diverse conditions but whether it has significance in its own right remains uncertain. We examined whether nocturia was an independent risk factor for mortality METHODS: These were observational analyses employing primarily North American and European participants and included 7343 men, aged 50-75 years participating in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial. Cox proportional hazards models were used to test the association between baseline nocturia (voiding ≥3 times per night) and all-cause mortality...
September 13, 2018: Prostate Cancer and Prostatic Diseases
Chang Wook Jeong, Minyong Kang, Seung Il Jung, Tae-Hwan Kim, Sung Woo Park, Jae Young Joung, Seong Soo Jeon, Jun Hyuk Hong, Ji Youl Lee, Byung Ha Chung, Hanjong Ahn, Choung-Soo Kim, Dong Deuk Kwon, Cheol Kwak
BACKGROUND: Enzalutamide can significantly prolong the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). However, there is a paucity of evidence on continuing androgen-deprivation therapy (ADT) for mCRPC. Here, we analyzed the effect of concomitant ADT during enzalutamide treatment in men with mCRPC following chemotherapy. METHODS: We retrospectively reviewed the medical records of 232 patients with mCRPC who received oral enzalutamide (160 mg per day) following chemotherapy at 9 tertiary centers in Korea between 2014 and 2016...
September 13, 2018: Prostate Cancer and Prostatic Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"